| First author | Reference | Country | HPV DNA source | PCR primers | Cases n | LSIL/CIN1 | HPV prevalence (% of all LSILs tested) | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any | 16 | 31 | 51 | 53 | 56 | 52 | 66 | 58 | 6 | 18 | 39 | 33 | 59 | 35 | 45 | |||||||||||||||||||||||||||||
| Africa | ||||||||||||||||||||||||||||||||||||||||||||
| de Vuyst H | Sex Transm Dis (2002) | Kenya | Cells | SPF10 | 30 | 0/30 | 60.0 | 13.3 | 3.3 | 3.3 | 10.0 | 3.3 | 13.3 | 3.3 | 6.7 | 0.0 | 6.7 | 0.0 | 0.0 | 0.0 | 23.3 | 3.3 | ||||||||||||||||||||||
| La Ruche G | Int J Cancer (1998) | Ivory Coast | Cells | MY09/11 | 151 | 151/0 | 68.2 | 10.6 | 5.3 | 0.0 | — | 2.6 | 2.6 | — | 3.3 | 3.3 | 6.0 | 2.0 | 5.3 | 1.3 | 1.3 | 2.0 | ||||||||||||||||||||||
| Thomas JO | Br J Cancer (2003) | Nigeria | Cells | GP5+/6+ | 34 | 34/0 | 38.2 | 5.9 | 2.9 | 2.9 | — | 2.9 | 2.9 | 0.0 | 5.9 | 2.9 | 2.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||||||||||||||||||||
| Xi LF | Int J Cancer (2003) | Senegal | Cells | MY09/11 | 86 | 86/0 | 51.2 | 8.1 | 1.2 | 1.2 | 3.5 | 1.2 | 3.5 | 1.2 | 9.3 | 2.3 | 4.7 | 0.0 | 2.3 | 2.3 | 2.3 | 0.0 | ||||||||||||||||||||||
| Africa subtotal | 301 | 271/30 | 59.1 | 9.6 | 3.6 | 1.0 | 5.2 | 2.3 | 4.0 | 1.3 | 5.6 | 2.7 | 5.3 | 1.0 | 3.3 | 1.3 | 3.7 | 1.3 | ||||||||||||||||||||||||||
| Asia | ||||||||||||||||||||||||||||||||||||||||||||
| Bhattarakosol P | J Med Assoc Thai (2002) | Thailand | Biopsies | MY09/11 | 27 | 0/27 | 33.3 | 0.0 | — | — | — | — | — | — | 0.0 | 3.7 | — | 0.0 | — | — | — | |||||||||||||||||||||||
| Chan PKS | J Med Virol (1999) | China | Cells | MY09/11 | 51 | 0/51 | 64.7 | 21.6 | 7.8 | 0.0 | 0.0 | 2.0 | 5.9 | 0.0 | 15.7 | 2.0 | 9.8 | 0.0 | 2.0 | 0.0 | 0.0 | 0.0 | ||||||||||||||||||||||
| Chan PKS | J Med Virol (1999) | China | Cells | MY09/11 | 51 | 0/51 | 64.7 | 21.6 | 7.8 | 0.0 | 0.0 | 2.0 | 5.9 | 0.0 | 15.7 | 2.0 | 9.8 | 0.0 | 2.0 | 0.0 | 0.0 | 0.0 | ||||||||||||||||||||||
| Cho NH | Am J Obstet Gynecol (2003) | Korea | Cells | GP5+/6+ | 150 | 150/0 | 73.3 | 26.7 | 1.3 | 5.3 | — | 6.0 | 2.7 | 0.7 | 10.0 | 0.7 | 7.3 | 4.0 | 0.7 | 0.0 | 2.0 | 1.3 | ||||||||||||||||||||||
| Hwang TS | Gynecol Oncol (2003) | Korea | Cells | GP5+/6+ | 24 | 0/24 | 70.8 | 16.7 | 0.0 | 4.2 | — | 4.2 | 4.2 | 4.2 | 0.0 | 0.0 | 16.7 | 8.4 | 0.0 | 0.0 | 4.2 | 0.0 | ||||||||||||||||||||||
| Asia subtotal | 252 | 150/102 | 67.1 | 21.8 | 2.7 | 4.0 | 0.0 | 4.9 | 3.6 | 2.2 | 10.2 | 0.8 | 7.1 | 3.6 | 0.8 | 0.0 | 1.8 | 0.9 | ||||||||||||||||||||||||||
| Europe | ||||||||||||||||||||||||||||||||||||||||||||
| Astori G | Virus Res (1997) | Italy | Cells | MY09/11 | 111 | 111/0 | 77.5 | 24.3 | 5.4 | 0.0 | 7.2 | 0.9 | 0.0 | 0.0 | 7.2 | 10.8 | 5.4 | 0.9 | 0.0 | 0.9 | 1.8 | 0.0 | ||||||||||||||||||||||
| Baay MFD | Eur J Gynaecol Oncol (2001) | Belgium | Biopsies | GP5+/6+ | 58 | 0/58 | 69.0 | 24.1 | 1.7 | 3.4 | — | 5.2 | 1.7 | 1.7 | 0.0 | 0.0 | 19.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.2 | ||||||||||||||||||||||
| Cuschieri KS | J Clin Pathol (2004) | United Kingdom | Cells | GP5+/6+ | 243 | 243/0 | 90.9 | 28.0 | 12.8 | 17.3 | — | 9.9 | 12.3 | 11.9 | 5.0 | 0.0 | 9.5 | 9.1 | 7.4 | 8.6 | 2.1 | 5.3 | ||||||||||||||||||||||
| Cuzick J | Br J Cancer (1999) | United Kingdom | Cells | MY09/11 | 50 | 0/50 | 42.0 | 12.0 | 0.0 | 2.0 | — | 4.0 | 12.0 | — | 2.0 | — | 10.0 | — | 2.0 | — | 0.0 | — | ||||||||||||||||||||||
| Giannoudis A | Int J Cancer (1999) | United Kingdom | Biopsies | GP5+/6+ | 118 | 118/0 | 100.0 | 12.7 | 5.1 | 7.6 | — | 5.9 | — | 11.9 | 7.6 | 15.3 | 7.6 | 0.8 | 0.8 | 2.5 | 14.4 | 2.5 | ||||||||||||||||||||||
| Grce M | Eur J Epidemiol (1997) | Croatia | Cells | MY09/11 | 183 | 183/0 | 35.5 | 6.0 | 8.7 | — | — | — | — | — | — | — | 2.2 | — | 1.6 | — | — | — | ||||||||||||||||||||||
| Grce M | Anticancer Res (2001) | Croatia | Cells | MY09/11 | 1,028 | 1,028/0 | 54.5 | 11.6 | 5.8 | — | — | — | — | — | — | — | 2.9 | — | 3.1 | — | — | — | ||||||||||||||||||||||
| Humbey O | Eur J Obstet Gynecol Reprod Biol (2002) | France | Cells | MY09/11 | 40 | 40/0 | 60.0 | 30.0 | — | 5.0 | — | — | 5.0 | — | 7.5 | 2.5 | 10.0 | — | 7.5 | — | 2.5 | 2.5 | ||||||||||||||||||||||
| Kalantari M | Hum Pathol (1997) | Sweden | Cells | MY09/11 | 141 | 0/141 | 70.9 | 17.7 | 5.7 | — | — | — | — | — | — | — | 12.1 | — | 5.0 | — | — | — | ||||||||||||||||||||||
| Labropoulou V | Sex Transm Dis (1997) | Greece | Biopsies/cells | MY09/11 | 51 | 0/51 | 90.2 | 11.8 | 9.8 | 0.0 | 2.0 | — | — | 2.0 | — | 11.8 | 11.8 | — | 9.8 | — | — | — | ||||||||||||||||||||||
| Laconi S | Pathologica (2000) | Italy | Biopsies | GP5+/6+ | 20 | 0/20 | 95.0 | 30.0 | 0.0 | 20.0 | — | 0.0 | 0.0 | — | 0.0 | 10.0 | 0.0 | 0.0 | 0.0 | — | 0.0 | — | ||||||||||||||||||||||
| Medeiros R | Int Meet Gynecol Oncol (1997) | Portugal | Biopsies | MY09/11 | 31 | 0/31 | 74.2 | 35.5 | — | — | — | — | — | — | — | — | 3.2 | — | 0.0 | — | — | — | ||||||||||||||||||||||
| Meyer T | Int J Gynecol Cancer (2001) | Germany | Biopsies/cells | MY09/11 | 130 | 130/0 | 69.2 | 13.1 | 13.1 | 3.1 | 2.3 | 0.8 | 3.1 | 3.8 | 5.4 | 3.1 | 2.3 | 1.5 | 5.4 | 0.0 | 3.1 | 0.8 | ||||||||||||||||||||||
| Nindl I | J Clin Pathol (1999) | Germany | Cells | GP5+/6+ | 49 | 0/49 | 53.1 | 12.2 | 2.0 | 4.1 | — | 4.1 | 0.0 | 2.0 | 8.2 | — | 0.0 | 2.0 | 6.1 | 0.0 | 0.0 | 4.1 | ||||||||||||||||||||||
| Reesink-Peters N | Eur J Obstet Gynecol Reprod Biol (2001) | Netherlands | Cells | SPF10 | 35 | 0/35 | 97.1 | 28.6 | 31.4 | — | — | 11.4 | — | — | — | — | 31.4 | — | 17.1 | — | — | — | ||||||||||||||||||||||
| Southern S | Hum Pathol (2001) | United Kingdom | Biopsies | GP5+/6+ | 49 | 0/49 | 100.0 | 10.2 | 2.0 | 4.1 | — | 2.0 | 6.1 | 6.1 | 10.2 | 24.5 | 8.2 | 4.1 | 2.0 | 0.0 | 0.0 | 0.0 | ||||||||||||||||||||||
| Tachezy R | J Med Virol (1999) | Czech Republic | Cells | MY09/11 | 87 | 87/0 | 52.9 | 34.5 | 2.3 | 1.1 | 2.3 | 0.0 | 1.1 | 0.0 | 5.7 | — | 4.6 | 0.0 | 2.3 | 0.0 | 2.3 | 1.1 | ||||||||||||||||||||||
| Venturoli S | J Clin Virol (2002) | Italy | Cells | MY09/11 | 40 | 40/0 | 47.5 | 7.5 | 10.0 | — | — | — | — | — | — | 5.0 | 2.5 | — | 2.5 | — | — | 0.0 | ||||||||||||||||||||||
| Voglino G | Pathologica (2000) | Italy | Biopsies | MY09/11 | 1,499 | 0/1,499 | 73.0 | 24.7 | 15.9 | — | — | — | — | — | — | — | 4.2 | — | 8.9 | — | 4.3 | — | ||||||||||||||||||||||
| Zehbe I | Virchows Arch (1996) | Sweden | Biopsies | GP5+/6+ | 45 | 0/45 | 93.3 | 40.0 | 11.1 | — | — | 6.7 | 2.2 | — | 6.7 | 6.7 | 6.7 | — | 2.2 | — | 2.2 | 0.0 | ||||||||||||||||||||||
| Zerbini M | J Clin Pathol (2001) | Italy | Cells | MY09/11 | 43 | 43/0 | 53.5 | 14.0 | 4.7 | — | — | — | — | — | — | 9.3 | 0.0 | — | 9.3 | — | — | 2.3 | ||||||||||||||||||||||
| Europe subtotal | 4,051 | 2,023/2,028 | 67.8 | 19.4 | 10.4 | 6.9 | 3.7 | 4.8 | 5.4 | 6.0 | 5.7 | 6.8 | 5.1 | 3.4 | 5.7 | 3.0 | 3.8 | 2.5 | ||||||||||||||||||||||||||
| North America | ||||||||||||||||||||||||||||||||||||||||||||
| Adam E | Am J Obstet Gynecol (2000) | United States | Cells | MY09/11 | 161 | 0/161 | 72.7 | 45.3 | 3.1 | — | — | — | — | — | — | — | 23.6 | — | 6.2 | — | 17.4 | — | ||||||||||||||||||||||
| ASCUS-LSIL Triage Study Group | Am J Obstet Gynecol (2003) | United States | Cells | PGMY09/11 | 1,242 | 1,242/0 | 92.4 | 21.5 | 9.0 | 16.1 | 11.1 | 12.8 | 11.7 | 10.9 | 7.6 | 6.8 | 10.5 | 11.0 | 4.4 | 10.0 | 7.0 | 6.0 | ||||||||||||||||||||||
| Brown DR | Sex Transm Dis (2002) | United States | Cells | MY09/11 | 25 | 25/0 | 88.0 | 40.0 | 12.0 | 4.0 | 4.0 | 20.0 | 12.0 | 24.0 | 4.0 | 4.0 | 0.0 | 8.0 | 4.0 | 8.0 | 12.0 | 0.0 | ||||||||||||||||||||||
| Evans MF | Mod Pathol (2002) | United States | Biopsies | GP5+/6+ | 26 | 0/28 | 100.0 | 7.1 | 7.1 | 10.7 | 0.0 | 3.6 | 7.1 | 10.7 | 0.0 | 7.1 | 3.6 | 10.7 | 3.6 | 10.7 | 3.6 | 3.6 | ||||||||||||||||||||||
| Jarboe EA | Hum Pathol (2004) | United States | Cells | PGMY09/11 | 95 | 0/95 | 55.8 | 7.4 | 3.2 | 4.2 | 8.4 | 3.2 | 9.5 | 5.3 | 2.1 | 2.1 | 3.2 | 1.1 | 0.0 | 10.5 | 2.1 | 5.3 | ||||||||||||||||||||||
| Kulasingam S | JAMA (2002) | United States | Cells | MY09/11 | 166 | 166/0 | 79.0 | 15.7 | 3.6 | 15.0 | 11.4 | 7.2 | 8.4 | 9.0 | 5.4 | 10.2 | 3.6 | 7.8 | 3.0 | 3.6 | 4.2 | 2.4 | ||||||||||||||||||||||
| Liaw K | J Natl Cancer Inst (1999) | United States | Cells | MY09/11 | 173 | 173/0 | 42.2 | 7.5 | 4.0 | 6.4 | 4.6 | 4.6 | 1.7 | 1.2 | 3.5 | — | 1.7 | 2.9 | 1.7 | 0.0 | 1.7 | 1.2 | ||||||||||||||||||||||
| Richardson H | Cancer Epidemiol Biomarkers Prev (2003) | Canada | Cells | MY09/11 | 44 | 44/0 | 88.6 | 18.2 | 2.3 | 18.2 | 18.2 | 20.5 | 4.5 | 9.1 | 6.8 | 0.0 | 9.1 | 6.8 | 0.0 | 2.3 | 2.3 | 0.0 | ||||||||||||||||||||||
| Schiff M | Am J Epidemiol (2000) | United States | Cells | MY09/11 | 190 | 0/190 | 58.4 | 5.8 | 8.9 | 4.2 | 10.5 | 7.4 | 4.7 | 6.8 | 10.5 | 4.2 | 4.7 | 7.4 | 4.2 | 6.3 | 1.1 | 4.7 | ||||||||||||||||||||||
| Sellors JW | CMAJ (2000) | Canada | Cells | MY09/11 | 22 | 22/0 | 90.9 | 50.0 | 4.5 | 0.0 | 0.0 | 4.5 | 0.0 | — | 0.0 | 4.5 | 4.5 | 4.5 | 0.0 | 0.0 | 0.0 | 0.0 | ||||||||||||||||||||||
| Sellors JW | CMAJ (2000) | Canada | Cells | MY09/11 | 24 | 24/0 | 95.8 | 37.5 | 12.5 | 0.0 | 0.0 | 0.0 | 0.0 | — | 4.2 | 4.2 | 25.0 | 0.0 | 4.2 | 0.0 | 0.0 | 0.0 | ||||||||||||||||||||||
| Tortolero-Luna | Cad Saude Publica (1998) | United States | Cells | MY09/11 | 175 | 175/0 | 64.6 | 12.6 | 6.9 | — | — | — | — | — | — | — | 8.0 | — | — | — | 4.0 | 9.1 | ||||||||||||||||||||||
| Tran-Thanh D | Am J Obstet Gynecol (2003) | Canada | Biopsies | MY09/11 | 80 | 0/80 | 83.8 | 15.0 | 8.8 | 3.8 | 8.8 | 15.0 | 8.0 | 8.8 | 6.3 | 6.3 | 8.8 | 7.5 | 5.0 | 3.8 | 0.0 | 1.3 | ||||||||||||||||||||||
| North America subtotal | 2,425 | 1,872/554 | 80.2 | 19.4 | 7.4 | 12.6 | 10.1 | 10.7 | 9.3 | 9.3 | 6.8 | 6.3 | 9.2 | 8.8 | 3.9 | 7.6 | 5.8 | 5.0 | ||||||||||||||||||||||||||
| South/Central America | ||||||||||||||||||||||||||||||||||||||||||||
| Abba MC | Rev Argent Microbiol (2003) | Argentina | Cells | MY09/11 | 279 | 279/0 | 80.3 | 26.5 | 2.5 | 0.7 | — | — | — | — | — | 22.9 | 2.5 | — | 5.4 | — | — | — | ||||||||||||||||||||||
| Ferrera A | Int J Cancer (1999) | Honduras | Cells | MY09/11 | 44 | 0/44 | 47.7 | 11.4 | 11.4 | 0.0 | 4.5 | 0.0 | 0.0 | 0.0 | 2.3 | 0.0 | 6.8 | 0.0 | 0.0 | 0.0 | 0.0 | 2.3 | ||||||||||||||||||||||
| Franco E | Pan Am J Public Health (1999) | Brazil | Cells | MY09/11 | 27 | 27/0 | 81.5 | 26.0 | 11.0 | 14.8 | 14.8 | 3.7 | 11.1 | 0.0 | 11.1 | 0.0 | 0.0 | 3.7 | 3.7 | 3.7 | 3.7 | 0.0 | ||||||||||||||||||||||
| Giuliano A | Cancer Epidemiol Biomarkers Prev (2001) | Mexico (some United States) | Cells | PGMY09/11 | 40 | 40/0 | 62.5 | 15.0 | 0.0 | 7.5 | 2.5 | 5.0 | 7.5 | 5.0 | 5.0 | 2.5 | 2.5 | 10.0 | 0.0 | 7.5 | 2.5 | 2.5 | ||||||||||||||||||||||
| Gonzalez-Losa MdR | J Clin Virol (2004) | Mexico | Biopsies | MY09/11 | 104 | 104/0 | 28.8 | 5.8 | 2.9 | 1.9 | 2.9 | 1.0 | 1.9 | 1.9 | 6.7 | 3.8 | 3.8 | 1.0 | 1.0 | 1.9 | 0.0 | 1.0 | ||||||||||||||||||||||
| Herrero R | J Natl Cancer Inst (2000) | Costa Rica | Cells | MY09/11 | 181 | 181/0 | 73.0 | 12.2 | 7.2 | 9.9 | 6.1 | 8.8 | 7.2 | 4.4 | 8.8 | 6.1 | 4.4 | 6.6 | 1.1 | 1.7 | 2.2 | 3.9 | ||||||||||||||||||||||
| Illades-Aguiar B | Int Papillomarivus Conf Proc (2001) | Mexico | Biopsies | MY09/11 | 148 | 0/148 | 86.5 | 12.8 | 2.0 | 0.0 | 0.7 | 0.0 | 0.7 | 0.0 | 3.4 | 2.0 | 0.7 | 0.0 | 36.5 | 0.0 | 0.7 | 4.1 | ||||||||||||||||||||||
| Lorenzato F | Int J Gynecol Cancer (2000) | Brazil | Cells | MY09/11 | 62 | 0/62 | 67.7 | 19.4 | 22.6 | — | — | — | 0.0 | — | 6.5 | 0.0 | 3.2 | — | 11.3 | — | 4.8 | 0.0 | ||||||||||||||||||||||
| Molano J | Br J Cancer (2002) | Colombia | Cells | GP5+/6+ | 70 | 70/0 | 55.7 | 10.0 | 4.3 | 4.3 | — | 4.3 | 7.1 | 1.4 | 5.7 | 2.9 | 7.1 | 4.3 | 8.6 | 0.0 | 2.9 | 4.3 | ||||||||||||||||||||||
| Rattray C | J Infect Dis (1996) | Jamaica | Cells | MY09/11 | 62 | 62/0 | 80.6 | 9.7 | 8.1 | — | — | — | — | — | — | 4.8 | 4.8 | — | 12.9 | — | 8.1 | 16.1 | ||||||||||||||||||||||
| Strickler H | J Med Virol (1999) | Jamaica | Cells | MY09/11 | 186 | 186/0 | 54.3 | 4.3 | 1.6 | 1.6 | 2.7 | 1.6 | 2.7 | 2.2 | 2.2 | 2.2 | 2.7 | 1.6 | 1.6 | 0.5 | 2.2 | 0.5 | ||||||||||||||||||||||
| Tonon SA | Infect Dis Obstet Gynecol (1999) | Argentina/Paraguay | Cells | GP5+/6+ | 55 | 55/0 | 96.4 | 74.5 | — | — | — | — | — | — | — | 5.5 | 12.7 | — | — | — | — | — | ||||||||||||||||||||||
| Torroella-Kouri M | Gynecol Oncol (1998) | Mexico | Biopsies/cells | MY09/11 | 21 | 21/0 | 33.3 | 4.8 | 0.0 | 4.8 | 0.0 | 4.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.8 | ||||||||||||||||||||||
| South/Central America subtotal | 1,279 | 1,025/254 | 68.3 | 16.7 | 4.8 | 3.3 | 3.6 | 3.3 | 3.6 | 2.1 | 5.2 | 7.4 | 3.6 | 2.9 | 7.9 | 1.2 | 2.2 | 3.3 | ||||||||||||||||||||||||||
| Total | 8,308 | 5,341/2,967 | 71.2 | 18.7 | 8.2 | 8.0 | 7.6 | 7.2 | 6.7 | 6.5 | 6.3 | 6.2 | 6.1 | 5.8 | 5.3 | 4.6 | 4.3 | 3.7 | ||||||||||||||||||||||||||
* HPV prevalence represents that at study enrollment and not at LSIL diagnosis.